First comparative randomized ASD study published

A new multicentric, randomized study compares the Occlutech Figulla Flex-II Occluder (OFFII) versus the Amplatzer Septal Occluder (ASO) for percutaneous ASD closure.

The trial results prove non-inferiority of the OFFII with less complications and a better efficacy than the ASO.

- **176 randomized patients**: 107 OFFII / 51 ASO in 7 sites in Ireland, Germany, United Kingdom and Qatar.
- The OFFII is proven as non-inferior with **less complications and a better efficacy** than the ASO in children > 8 kg
- The primary endpoint: **Higher early efficacy success** for the OFFII (94.8% vs. 88.1%)
- Complication rates were 5.6% for the OFFII group compared to 9.8% for the ASO
- Despite all the objections on delivery sheath size, in this study the size of occluders was not associated with greater vascular complications in the OFFII cohort since it is the **OUTER DIAMETER** that matters!

Successful device placement on the first attempt was significantly higher in the OFFII group (99.1% vs. 90.2% (P < 0.05)). Discussed are the following reasons:

- **Softer left atrial disc**
- **Greater flexibility**
- **Greater operator confidence during deployment**

To access the article please check:


or consult your local Occlutech Representative
A randomized, controlled, multi-center trial of the efficacy and safety of the Occlutech Figulla Flex-II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects

Damien Kenny MD Andreas Eicken MD, PhD Ingo Dähnert MD, PhD Younes Boudjemline MD, PhD Horst Sievert MD, PhD Martin BE Schneider MD Tommaso Gori MD, PhD

Abstract

Aims

The aim of this study was to compare the efficacy and safety of the Occlutech Figulla Flex II Occluder (OFFII) with the Amplatzer Septal Occluder (ASO) in patients >8kg undergoing transcatheter ASD closure.

Methods and results

Randomized, controlled, multi-center prospective clinical trial with randomization 2:1 in favor of the OFFII. Primary efficacy endpoint was the rate of successful device placement and defect closure without major complications at hospital discharge. All data were assessed through a core laboratory. Interim analysis was performed when 70% of the patients were treated to evaluate for noninferiority.

From a total of 176 randomized subjects, interim analysis was performed on the first 158 patients (65.2% female) (107 OFFII/51 ASO) undergoing device closure at a median weight of 42 kg (range 13-125 kg). Seventy-six percent (120 patients) completed 6-month follow-up. Successful device placement (first attempt) was achieved in 99.1% of the OFF group vs 90.2% of the ASO group ($P<0.05$). Early efficacy success was achieved in 94.4% of the OFFII group vs 90.2% of the ASO group ($P<0.001$). The incidence of major complications was 5.6% for the OFFII group compared to 9.8% for the ASO.

Conclusions

The OFFII device was not inferior to the ASO with less complications and greater efficacy than the ASO.

First published: 04 November 2018

Catheterization & Cardiovascular Intervention

Wiley Online Library

https://doi.org/10.1002/ccd.27899